PolyMedix Message Board - Msg: 28707818

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PolyMedix

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	2/5/2013 12:33:05 PM
	of 77

PolyMedix Announces Departure of CEO, Appointment of Interim CEO RADNOR, Pa., Jan. 30, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB: PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobials, today announced that Nicholas Landekic's employment with the company has ceased and that he will be pursuing other interests. Mr. Landekic was the company's president and chief executive officer and Edward F. Smith, who has served as the company's chief financial officer since January 2006, has been appointed as the interim president and chief executive officer. PolyMedix remains committed to pursuing its strategic and financial alternatives in its efforts to increase stockholder value.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next